Monocytic differentiation induced by side-chain modified analogs of vitamin D in ex vivo cells from patients with acute myeloid leukemia

Leukemia Research

Volumn 38, Issue 5, 2014, Pages 638-647

  Baurska, Hanna ^a   Kiełbiński, Marek ^b   Biecek, Przemysław ^c   Haus, Olga ^d   Jaźwiec, Bozena ^b   Kutner, Andrzej ^e   Marcinkowska, Ewa ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF WARSAW   (Poland)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^e INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

Acute myeloid leukemia; Blasts; Differentiation; Flow cytometry; Personalized anticancer therapy; Statistical analysis; Vitamin D analogs

Indexed keywords

1 ;25-DIHYDROXYVITAMIN D(3); ACUTE MYELOID LEUKEMIA; BLASTS; DIFFERENTIATION; FLOW CYTOMETRY; PERSONALIZED ANTICANCER THERAPY; STATISTICAL ANALYSIS; VITAMIN D ANALOGS;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONOCYTES; MUTATION; VITAMIN D;

EID: 84899111269     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.03.009     Document Type: Article

References (34)

1. Craig C.M., Schiller G.J. Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. Blood Rev 2008, 22:221-234.
2. Wang Z., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
3. 3. Proc Nat Acad Sci USA 1981, 78:4990-4994.
4. Koeffler H. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 1983, 62:709-721.
5. 3 and its fluorinated analogues. Cancer Res 1984, 44:5624-5628.
6. Petrie K., Zelent A., Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009, 16:84-91.
7. 2 analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. Leuk Res 2005, 29:1259-1262.
8. 2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res 2005, 65:2488-2497.
9. Kim M., Mirandola L., Pandey A., Nguyen D., Jenkins M., Turcel M., et al. Application of vitamin D and derivatives in hematological malignancies. Cancer Lett 2012, 319:8-22.
10. Harrison J., Bershadskiy A. Clinical experience using vitamin D and analogs in the treatment of myelodysplasia and acute myeloid leukemia: a review of the literature. Leuk Res Treat 2012.
11. Luong Q., Koeffler H. Vitamin D compounds in leukemia. J Steroid Biochem Mol Biol 2005, 97:195-202.
12. Okamoto R., Akagi T., Koeffler H. Vitamin D compounds and myelodysplastic syndrome. Leuk Lymphoma 2008, 49:12-13.
13. Opolski A., Wietrzyk J., Chrobak A., Marcinkowska E., Wojdat E., Kutner A., et al. Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines. Anticancer Res 1999, 19:5217-5222.
14. 3. J Steroid Biochem Mol Biol 1998, 67:71-78.
15. 3-induced differentiation of AML cells carrying various mutations. Leuk Res 2010, 34:649-657.
16. 2 analogs as potential inducers of leukemia differentiation and inhibitors of prostate cancer proliferation. J Steroid Biochem Mol Biol 2011, 126:46-54.
17. Soszynska K., Mucha B., Debski R., Skonieczka K., Duszenko E., Koltan A., et al. The application of conventional cytogenetics, FISH, and RT-PCR to detect genetic changes in 70 children with ALL. Ann Hematol 2008, 87:991-1002.
18. Libura M., Filip A., Haus O. Molecular diagnostics of acute myeloblastic leukemia. Molecular aspects of hematologic malignancies principles and practice 2012, 387-410. Springer-Verlag, Berlin Heidelberg. M. Witt, M. Dawidowska, T. Szczepański (Eds.).
19. Team R.C. A language and environment for statistical computing 2013, Foundation for Statistical Computing, Vienna, Austria.
20. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995, 57:289-300.
21. 2. (24E)-(1S)-24-dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners. Steroids 2002, 67:789-798.
22. Studzinski G., Wang X., Ji Y., Wang Q., Zhang Y., Kutner A., et al. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. J Steroid Biochem Mol Biol 2005, 97:47-55.
23. 3. Anticancer Drugs 2007, 18:447-457.
24. Carlberg C., Seuter S., de Mello V., Schwab U., Voutilainen S., Pulkki K., et al. Primary vitamin D target genes allow a categorization of possible benefits of vitamin D3 supplementation. PLoS One 2013, e71042.
25. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematol Am Soc Hematol Educ Program 2008, 1-11.
26. Lowenberg B., Griffin J., Tallman M. Acute myeloid leukemia and acute promyelocytic leukemia. Hematol Am Soc Hematol Educ Program 2003, 82-101.
27. Gocek E., Marcinkowska E. Differentiation therapy of acute myeloid leukemia. Cancers 2011, 3:2402-2420.
28. Baurska H., Marchwicka A., Klopot A., Kutner A., Marcinkowska E. Studies on the mechanisms of superagonistic pro-differentiating activities of side-chain modified analogs of vitamin D2. Oncol Rep 2012, 28:1110-1116.
29. O'Neill J., Feldman S. Vitamine D analogue-based therapies for psoriasis. Drugs Today (Barc) 2010, 46:351-360.
30. Girolomoni G., Vena G., Ayala F., Cannavò S., De Pità O., Chimenti S., et al. Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis. G Ital Dermatol Venereol 2012, 147:609-624.
31. Devaux S., Castela A., Archier E., Gallini A., Joly P., Misery L., et al. Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2012, Suppl3:52-60.
32. Gocek E., Marchwicka A., Baurska H., Chrobak A., Marcinkowska E. Opposite regulation of vitamin D receptor by ATRA in AML cells susceptible and resistant to vitamin D-induced differentiation. J Steroid Biochem Mol Biol 2012, 132:220-226.
33. Stone R. Prognostic factors in AML in relation to (ab)normal karyotype. Best Prac Res Clin Haematol 2009, 22:523-528.
34. Verhaak R., Goudswaard C., van Putten W., Bijl M., Sanders M., Hugens W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005, 106:3747-3754.